

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**EC Healthcare**

**醫思健康**

*(Incorporated in the Cayman Islands with limited liability)*

*(Stock Code: 2138)*

## **DISCLOSEABLE TRANSACTION COMPLETION OF ACQUISITION OF MEDICAL BUSINESS**

Reference is made to the announcement of the Company dated 16 February 2022 in respect of the Acquisition (the “**Announcement**”). Unless the context otherwise stated, capitalised terms used in this announcement have the same meanings as those defined in the Announcement.

The Board is pleased to announce that on 31 March 2022, the completion of the Sale and Purchase Agreement took place, and the Consideration of HK\$68 million has been settled in full. After the Completion, the Target Company has become an indirect wholly-owned subsidiary of the Company and the financial results of the Target Company will be consolidated into the Group.

By order of the Board  
**EC Healthcare**  
**Raymond Siu**  
*Company Secretary*

Hong Kong, 31 March 2022

*As at the date of this announcement, the executive Directors are Mr. Tang Chi Fai, Mr. Lu Lyn Wade Leslie, Mr. Lee Heung Wing, Ms. Wong Ka Ki Ada, and Mr. Wong Chi Cheung; the non-executive Director is Mr. Luk Kun Shing Ben; and the independent non-executive Directors are Mr. Ma Ching Nam, Mr. Look Andrew and Mr. Lam Chi Hang Josekin.*